Search for other papers by Cheng-Hsuan Tsai in
Google Scholar
PubMed
Search for other papers by Zheng-Wei Chen in
Google Scholar
PubMed
Search for other papers by Bo-Ching Lee in
Google Scholar
PubMed
Search for other papers by Che-Wei Liao in
Google Scholar
PubMed
Search for other papers by Yi-Yao Chang in
Google Scholar
PubMed
Search for other papers by Yan-Rou Tsai in
Google Scholar
PubMed
Search for other papers by Chia-Hung Chou in
Google Scholar
PubMed
Search for other papers by Vin-Cent Wu in
Google Scholar
PubMed
Search for other papers by Chi-Sheng Hung in
Google Scholar
PubMed
Search for other papers by Yen-hung Lin in
Google Scholar
PubMed
Aldosterone is a mineralocorticoid hormone involved in controlling electrolyte balance, blood pressure and cellular signaling. It plays a pivotal role in cardiovascular and metabolic physiology. Excess aldosterone activates mineralocorticoid receptors, leading to subsequent inflammatory responses, increased oxidative stress, and tissue remodeling. Various mechanisms have been reported to link aldosterone with cardiovascular and metabolic diseases. However, mitochondria, responsible for energy generation through oxidative phosphorylation, have received less attention regarding their potential role in aldosterone-related pathogenesis. Excess aldosterone leads to mitochondrial dysfunction, and this may play a role in the development of cardiovascular and metabolic diseases. Aldosterone has the potential to affect mitochondrial structure, function, and dynamic processes, such as mitochondrial fusion and fission. In addition, aldosterone has been associated with the suppression of mitochondrial DNA, mitochondria-specific protein, and ATP production in the myocardium through mineralocorticoid receptor, nicotinamide adenine dinucleotide phosphate oxidase, and reactive oxygen species pathways. In this review, we explore the mechanisms underlying aldosterone-induced cardiovascular and metabolic mitochondrial dysfunction, including mineralocorticoid receptor activation and subsequent inflammatory responses, as well as increased oxidative stress. Furthermore, we review potential therapeutic targets aimed at restoring mitochondrial function in the context of aldosterone-associated pathologies. Understanding these mechanisms is vital, as it offers insights into novel therapeutic strategies to mitigate the impact of aldosterone-induced mitochondrial dysfunction, thereby potentially improving the outcomes of individuals affected by cardiovascular and metabolic disorders.
Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom
Search for other papers by Elisa Villalobos in
Google Scholar
PubMed
Search for other papers by Allende Miguelez-Crespo in
Google Scholar
PubMed
Scotland’s Rural College, The Roslin Institute, Easter Bush Campus, United Kingdom
Search for other papers by Ruth A Morgan in
Google Scholar
PubMed
Search for other papers by Lisa Ivatt in
Google Scholar
PubMed
Search for other papers by Mhairi Paul in
Google Scholar
PubMed
Search for other papers by Joanna P Simpson in
Google Scholar
PubMed
Search for other papers by Natalie Z M Homer in
Google Scholar
PubMed
Search for other papers by Dominic Kurian in
Google Scholar
PubMed
Search for other papers by Judit Aguilar in
Google Scholar
PubMed
Search for other papers by Rachel A Kline in
Google Scholar
PubMed
Search for other papers by Thomas M Wishart in
Google Scholar
PubMed
Centre for Systems Health and Integrated Metabolic Research, Nottingham Trent University, Nottingham, United Kingdom
Search for other papers by Nicholas M Morton in
Google Scholar
PubMed
Search for other papers by Roland H Stimson in
Google Scholar
PubMed
Search for other papers by Ruth Andrew in
Google Scholar
PubMed
Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom
Search for other papers by Brian R Walker in
Google Scholar
PubMed
Search for other papers by Mark Nixon in
Google Scholar
PubMed
Glucocorticoids modulate glucose homeostasis, acting on metabolically active tissues such as liver, skeletal muscle, and adipose tissue. Intracellular regulation of glucocorticoid action in adipose tissue impacts metabolic responses to obesity. ATP-binding cassette family C member 1 (ABCC1) is a transmembrane glucocorticoid transporter known to limit the accumulation of exogenously administered corticosterone in adipose tissue. However, the role of ABCC1 in the regulation of endogenous glucocorticoid action and its impact on fuel metabolism has not been studied. Here, we investigate the impact of Abcc1 deficiency on glucocorticoid action and high-fat-diet (HFD)-induced obesity. In lean male mice, deficiency of Abcc1 increased endogenous corticosterone levels in skeletal muscle and adipose tissue but did not impact insulin sensitivity. In contrast, Abcc1-deficient male mice on HFD displayed impaired glucose and insulin tolerance, and fasting hyperinsulinaemia, without alterations in tissue corticosterone levels. Proteomics and bulk RNA sequencing revealed that Abcc1 deficiency amplified the transcriptional response to an obesogenic diet in adipose tissue but not in skeletal muscle. Moreover, Abcc1 deficiency impairs key signalling pathways related to glucose metabolism in both skeletal muscle and adipose tissue, in particular those related to OXPHOS machinery and Glut4. Together, our results highlight a role for ABCC1 in regulating glucose homeostasis, demonstrating diet-dependent effects that are not associated with altered tissue glucocorticoid concentrations.
Search for other papers by Andrea Lovdel in
Google Scholar
PubMed
Search for other papers by Karla J Suchacki in
Google Scholar
PubMed
Search for other papers by Fiona Roberts in
Google Scholar
PubMed
Search for other papers by Richard J Sulston in
Google Scholar
PubMed
Search for other papers by Robert J Wallace in
Google Scholar
PubMed
Search for other papers by Benjamin J Thomas in
Google Scholar
PubMed
Search for other papers by Rachel M B Bell in
Google Scholar
PubMed
Search for other papers by Iris Pruñonosa Cervera in
Google Scholar
PubMed
Search for other papers by Gavin J Macpherson in
Google Scholar
PubMed
Centre for Systems Health and Integrated Metabolic Research, Department of Biosciences, School of Science and Technology, Nottingham Trent University, Nottingham, UK
Search for other papers by Nicholas M Morton in
Google Scholar
PubMed
Search for other papers by Natalie Z M Homer in
Google Scholar
PubMed
Search for other papers by Karen E Chapman in
Google Scholar
PubMed
Search for other papers by William P Cawthorn in
Google Scholar
PubMed
Bone marrow adipose tissue (BMAT) comprises >10% of total adipose mass in healthy humans. It increases in diverse conditions, including ageing, obesity, osteoporosis, glucocorticoid therapy, and notably, during caloric restriction (CR). BMAT potentially influences skeletal, metabolic, and immune functions, but the mechanisms of BMAT expansion remain poorly understood. Our hypothesis is that, during CR, excessive glucocorticoid activity drives BMAT expansion. The enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) amplifies glucocorticoid activity by catalysing intracellular regeneration of active glucocorticoids from inert 11-keto forms. Mice lacking 11β-HSD1 resist metabolic dysregulation and bone loss during exogenous glucocorticoid excess; thus, we hypothesised that 11β-HSD1 knockout mice would also resist excessive glucocorticoid action during CR, thereby restrining BMAT expansion and bone loss. To test this, we first confirmed that 11β-HSD1 is expressed in mouse and human bone marrow. We then investigated the effects of CR in male and female control and 11β-HSD1 knockout mice from 9 to 15 weeks of age. CR increased Hsd11b1 mRNA in adipose tissue and bone marrow. Deletion of Hsd11b1 did not alter bone or BMAT characteristics in mice fed a control diet and had little effect on tibial bone microarchitecture during CR. Notably, Hsd11b1 deletion attenuated the CR-induced increases in BMAT and prevented increases in bone marrow corticosterone in males but not females. This was not associated with suppression of glucocorticoid target genes in bone marrow. Instead, knockout males had increased progesterone in plasma and bone marrow. Together, our findings show that knockout of 11β-HSD1 prevents CR-induced BMAT expansion in a sex-specific manner and highlights progesterone as a potential new regulator of bone marrow adiposity.
Search for other papers by Nawal A Yahya in
Google Scholar
PubMed
Department of Cell Biology and Biochemistry, Texas Tech University Health Sciences Center, Lubbock, Texas, USA
Search for other papers by Steven R King in
Google Scholar
PubMed
Search for other papers by Bo Shi in
Google Scholar
PubMed
Search for other papers by Aisha Shaaban in
Google Scholar
PubMed
Search for other papers by Nicole E Whitfield in
Google Scholar
PubMed
Department of Obstetrics, The Second Hospital of Shandong University, Jinan, Shandong, People’s Republic of China
Search for other papers by Chunmei Yan in
Google Scholar
PubMed
Search for other papers by Richard J Kordus in
Google Scholar
PubMed
Search for other papers by Gail F Whitman-Elia in
Google Scholar
PubMed
Search for other papers by Holly A LaVoie in
Google Scholar
PubMed
Cells actively engaged in de novo steroidogenesis rely on an expansive intracellular network to efficiently transport cholesterol. The final link in the transport chain is STARD1, which transfers cholesterol to the enzyme complex that initiates steroidogenesis. However, the regulation of ovarian STARD1 is not fully characterized, and even less is known about the upstream cytosolic cholesterol transporters STARD4 and STARD6. Here, we identified both STARD4 and STARD6 mRNAs in the human ovary but only detected STARD4 protein since the primary STARD6 transcript turned out to be a splice variant. Corpora lutea contained the highest levels of STARD4 and STARD1 mRNA and STARD1 protein, while STARD4 protein was uniformly distributed across ovarian tissues. Cyclic AMP analog (8Br-cAMP) and phorbol ester (PMA) individually increased STARD1 and STARD4 mRNA along with STARD1 protein and its phosphoform in cultured primary human luteinized granulosa cells (hGCs). STARD6 transcripts and STARD4 protein were unresponsive to these stimuli. Combining lower doses of PMA and 8Br-cAMP blunted the 8Br-cAMP stimulation of STARD1 protein. Increasing cholesterol levels by blocking its conversion to steroid with aminoglutethimide or by adding LDL reduced the STARD4 mRNA response to stimuli. Sterol depletion reduced the STARD1 mRNA and protein response to PMA. These data support a possible role for STARD4, but not STARD6, in supplying cholesterol for steroidogenesis in the ovary. We demonstrate for the first time how cAMP, PMA and sterol pathways separately and in combination differentially regulate STARD4, STARD6 and STARD1 mRNA levels, as well as STARD1 and STARD4 protein in human primary ovarian cells.
Search for other papers by Ryan A Lafferty in
Google Scholar
PubMed
Search for other papers by Peter R Flatt in
Google Scholar
PubMed
Search for other papers by Victor A Gault in
Google Scholar
PubMed
Search for other papers by Nigel Irwin in
Google Scholar
PubMed
Recent approval of the dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, tirzepatide, for the management of type 2 diabetes mellitus (T2DM) has reinvigorated interest in exploitation of GIP receptor (GIPR) pathways as a means of metabolic disease management. However, debate has long surrounded the use of the GIPR as a therapeutic target and whether agonism or antagonism is of most benefit in management of obesity/diabetes. This controversy appears to be partly resolved by the success of tirzepatide. However, emerging studies indicate that prolonged GIPR agonism may desensitise the GIPR to essentially induce receptor antagonism, with this phenomenon suggested to be more pronounced in the human than rodent setting. Thus, deliberation continues to rage in relation to benefits of GIPR agonism vs antagonism. That said, as with GIPR agonism, it is clear that the metabolic advantages of sustained GIPR antagonism in obesity and obesity-driven forms of diabetes can be enhanced by concurrent GLP-1 receptor (GLP-1R) activation. This narrative review discusses various approaches of pharmacological GIPR antagonism including small molecule, peptide, monoclonal antibody and peptide-antibody conjugates, indicating stage of development and significance to the field. Taken together, there is little doubt that interesting times lie ahead for GIPR agonism and antagonism, either alone or when combined with GLP-1R agonists, as a therapeutic intervention for the management of obesity and associated metabolic disease.
Search for other papers by Lorena González in
Google Scholar
PubMed
Search for other papers by Ma Eugenia Díaz in
Google Scholar
PubMed
Search for other papers by Johanna G Miquet in
Google Scholar
PubMed
Search for other papers by Ana I Sotelo in
Google Scholar
PubMed
Search for other papers by Diego Fernández in
Google Scholar
PubMed
Search for other papers by Fernando P Dominici in
Google Scholar
PubMed
Search for other papers by Andrzej Bartke in
Google Scholar
PubMed
Search for other papers by Daniel Turyn in
Google Scholar
PubMed
Search for other papers by Neerav Mullur in
Google Scholar
PubMed
Search for other papers by Arianne Morissette in
Google Scholar
PubMed
Search for other papers by Nadya Morrow in
Google Scholar
PubMed
Search for other papers by Erin Mulvhill in
Google Scholar
PubMed
Cardiovascular outcome trials (CVOTs) in people living with T2DM and obesity have confirmed the cardiovascular benefits of glucagon-like peptide 1 receptor agonists (GLP-1RA), including reduced cardiovascular mortality, lower rates of myocardial infarction, and lower rates of stroke. The cardiovascular benefits observed following GLP-1RA treatment could be secondary to improvements in glycemia, blood pressure, postprandial lipidemia, and inflammation. Yet, the GLP-1R is also expressed in the heart and vasculature, suggesting that GLP-1R agonism may impact the cardiovascular system. The emergence of GLP-1RA combined with glucose-dependant insulinotropic polypeptide (GIP) and glucagon (GCG) receptor agonists has shown promising results as new weight loss medications. Dual-agonist and tri-agonist therapies have demonstrated superior outcomes in weight loss, lowered blood sugar and lipid levels, restoration of tissue function, and enhancement of overall substrate metabolism compared to using GLP-1R agonists alone. However, the precise mechanisms underlying their cardiovascular benefits remain to be fully elucidated. This review aims to summarize the findings from CVOTs of GLP-1RAs, explore the latest data on dual and triagonist therapies, and delve into potential mechanisms contributing to their cardioprotective effects. It also addresses current gaps in understanding and areas for further research.
VCA Colonial Animal Hospital, Ithaca, New York, USA
Search for other papers by Michael Merkhassine in
Google Scholar
PubMed
Weill Cornell College of Medicine, New York, New York, USA
Search for other papers by Reilly W Coch in
Google Scholar
PubMed
Search for other papers by Carol E Frederick in
Google Scholar
PubMed
Search for other papers by Lucinda L Bennett in
Google Scholar
PubMed
Fate Therapeutics, San Diego, California, USA
Search for other papers by Seth A Peng in
Google Scholar
PubMed
Search for other papers by Benjamin Morse in
Google Scholar
PubMed
Department of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, Davis, California, USA
Search for other papers by Bethany P Cummings in
Google Scholar
PubMed
Search for other papers by John P Loftus in
Google Scholar
PubMed
Glucagon plays a central role in amino acid (AA) homeostasis. The dog is an established model of glucagon biology, and recently, metabolomic changes in people associated with glucagon infusions have been reported. Glucagon also has effects on the kidney; however, changes in urinary AA concentrations associated with glucagon remain under investigation. Therefore, we aimed to fill these gaps in the canine model by determining the effects of glucagon on the canine plasma metabolome and measuring urine AA concentrations. Employing two constant rate glucagon infusions (CRI) – low-dose (CRI-LO: 3 ng/kg/min) and high-dose (CRI-HI: 50 ng/kg/min) on five research beagles, we monitored interstitial glucose and conducted untargeted liquid chromatography–tandem mass spectrometry (LC-MS/MS) on plasma samples and urine AA concentrations collected pre- and post-infusion. The CRI-HI induced a transient glucose peak (90–120 min), returning near baseline by infusion end, while only the CRI-LO resulted in 372 significantly altered plasma metabolites, primarily reductions (333). Similarly, CRI-HI affected 414 metabolites, with 369 reductions, evidenced by distinct clustering post-infusion via data reduction (PCA and sPLS-DA). CRI-HI notably decreased circulating AA levels, impacting various AA-related and energy-generating metabolic pathways. Urine analysis revealed increased 3-methyl-l-histidine and glutamine, and decreased alanine concentrations post-infusion. These findings demonstrate glucagon’s glucose-independent modulation of the canine plasma metabolome and highlight the dog’s relevance as a translational model for glucagon biology. Understanding these effects contributes to managing dysregulated glucagon conditions and informs treatments impacting glucagon homeostasis.
Alberta Diabetes Institute, University of Alberta, Edmonton, Alberta, Canada
Cardiovascular Research Institute, University of Alberta, Edmonton, Alberta, Canada
Search for other papers by Jordan S F Chan in
Google Scholar
PubMed
Alberta Diabetes Institute, University of Alberta, Edmonton, Alberta, Canada
Cardiovascular Research Institute, University of Alberta, Edmonton, Alberta, Canada
Search for other papers by Amanda A Greenwell in
Google Scholar
PubMed
Alberta Diabetes Institute, University of Alberta, Edmonton, Alberta, Canada
Cardiovascular Research Institute, University of Alberta, Edmonton, Alberta, Canada
Search for other papers by Christina T Saed in
Google Scholar
PubMed
Alberta Diabetes Institute, University of Alberta, Edmonton, Alberta, Canada
Cardiovascular Research Institute, University of Alberta, Edmonton, Alberta, Canada
Search for other papers by Magnus J Stenlund in
Google Scholar
PubMed
Alberta Diabetes Institute, University of Alberta, Edmonton, Alberta, Canada
Cardiovascular Research Institute, University of Alberta, Edmonton, Alberta, Canada
Search for other papers by Indiresh A Mangra-Bala in
Google Scholar
PubMed
Alberta Diabetes Institute, University of Alberta, Edmonton, Alberta, Canada
Cardiovascular Research Institute, University of Alberta, Edmonton, Alberta, Canada
Search for other papers by Seyed Amirhossein Tabatabaei Dakhili in
Google Scholar
PubMed
Alberta Diabetes Institute, University of Alberta, Edmonton, Alberta, Canada
Cardiovascular Research Institute, University of Alberta, Edmonton, Alberta, Canada
Search for other papers by Kunyan Yang in
Google Scholar
PubMed
Alberta Diabetes Institute, University of Alberta, Edmonton, Alberta, Canada
Cardiovascular Research Institute, University of Alberta, Edmonton, Alberta, Canada
Search for other papers by Sally R Ferrari in
Google Scholar
PubMed
Alberta Diabetes Institute, University of Alberta, Edmonton, Alberta, Canada
Cardiovascular Research Institute, University of Alberta, Edmonton, Alberta, Canada
Search for other papers by Farah Eaton in
Google Scholar
PubMed
Alberta Diabetes Institute, University of Alberta, Edmonton, Alberta, Canada
Cardiovascular Research Institute, University of Alberta, Edmonton, Alberta, Canada
Search for other papers by Keshav Gopal in
Google Scholar
PubMed
Alberta Diabetes Institute, University of Alberta, Edmonton, Alberta, Canada
Cardiovascular Research Institute, University of Alberta, Edmonton, Alberta, Canada
Search for other papers by John R Ussher in
Google Scholar
PubMed
Liraglutide, a glucagon-like peptide-1 receptor (GLP-1R) agonist used for the treatment of T2D, has been shown to alleviate diabetic cardiomyopathy (DbCM) in experimental T2D, which was associated with increased myocardial glucose oxidation. To determine whether this increase in glucose oxidation is necessary for cardioprotection, we hypothesized that liraglutide’s ability to alleviate DbCM would be abolished in mice with cardiomyocyte-specific deletion of pyruvate dehydrogenase (PDH; Pdha1 CM−/− mice), the rate-limiting enzyme of glucose oxidation. Male Pdha1 CM−/− mice and their α-myosin heavy chain Cre expressing littermates (αMHCCre mice) were subjected to experimental T2D via 10 weeks of high-fat diet supplementation, with a single low-dose injection of streptozotocin (75 mg/kg) provided at week 4. All mice were randomized to treatment with either vehicle control or liraglutide (30 µg/kg) twice daily during the final 2.5 weeks, with cardiac function assessed via ultrasound echocardiography. As expected, liraglutide treatment improved glucose homeostasis in both αMHCCre and Pdha1 CM−/− mice with T2D, in the presence of mild weight loss. Parameters of systolic function were unaffected by liraglutide treatment in both αMHCCre and Pdha1 CM−/− mice with T2D. However, liraglutide treatment alleviated diastolic dysfunction in αMHCCre mice, as indicated by an increase and decrease in the e′/a′ and E/e′ ratios, respectively. Conversely, liraglutide failed to rescue these indices of diastolic dysfunction in Pdha1 CM−/− mice. Our findings suggest that increases in glucose oxidation are necessary for GLP-1R agonist mediated alleviation of DbCM. As such, strategies aimed at increasing PDH activity may represent a novel approach for the treatment of DbCM.
Department of Obstetrics and Gynecology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, China
Search for other papers by Yu Zhou in
Google Scholar
PubMed
Search for other papers by Chao Lian in
Google Scholar
PubMed
Search for other papers by Yingfei Lu in
Google Scholar
PubMed
Search for other papers by Tianming Wang in
Google Scholar
PubMed
Search for other papers by Chengcheng Zhao in
Google Scholar
PubMed
Search for other papers by Cuilan Zhang in
Google Scholar
PubMed
Search for other papers by Min Gong in
Google Scholar
PubMed
Department of Obstetrics and Gynecology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, China
Search for other papers by Jianquan Chen in
Google Scholar
PubMed
Search for other papers by Rong Ju in
Google Scholar
PubMed
Polycystic ovary syndrome (PCOS) is a condition resulting from the interaction between environmental factors and hereditary components, profoundly affecting offspring development. Although the etiology of this disease remains unclear, aberrant in utero androgen exposure is considered one of the pivotal pathogenic factors. Herein, we demonstrate the intergenerational inheritance of PCOS-like phenotypes in F2 female offspring through F1 males caused by maternal testosterone exposure in F0 mice. We found impaired serum hormone expression and reproductive system development in prenatal testosterone-treated F1 male and F2 female mice (PTF1 and PTF2). In addition, downregulated N6-methyladenosine (m6A) methyltransferase and binding proteins induced mRNA hypomethylation in the PTF1 testis, including frizzled-6 (Fzd6). In the PTF2 ovary, decreased FZD6 protein expression inhibited the mammalian target of rapamycin (mTOR) signaling pathway and activated Forkhead box O3 (FoxO3) phosphorylation, which led to impaired follicular development. These data indicate that epigenetic modification of the mTOR signaling pathway could be involved in the intergenerational inheritance of maternal testosterone exposure-induced impairments in the PTF2 ovary through male PTF1 mice.
